ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1390

One-year Real World Evidence Outcomes from the Cohort RADIUS (Real-world Analysis of Upadacitinib in Rheumatoid Arthritis Patients for Improved Understanding and Safety)
Abstract Number: 1391

Possible Mechanistic Pathways of the Effective “Plants for Joints” Lifestyle and Dietary Intervention for Rheumatoid Arthritis
Abstract Number: 1392

Safety and Efficacy of Upadacitinib (UPA) in Japanese Patients with Rheumatoid Arthritis (RA) and Inadequate Response to Conventional Synthetic DMARDs: Results Through 5 Years from the SELECT-SUNRISE Study
Abstract Number: 1393

Relationship Between Disease Activity and Adverse Events in Rheumatoid Arthritis: An Integrated Post Hoc Analysis of Upadacitinib Phase 3 Trials
Abstract Number: 1394

Nationwide Retrospective Cohort Study on Clinical Outcomes in Rheumatoid Arthritis Patients Treated with JAK Inhibitors
Abstract Number: 1395

Effects of Butyrate Supplementation in Modulation of Gut Microbiome and Its Metabolites in New Onset Rheumatoid Arthritis
Abstract Number: 1396

Low CD47 Expression on B Cells, Induces High B Cell Phagocytosis by Macrophages and Is a Predictive Biomarker of Anti-rituximab Antibodies and Lower Response in Rheumatoid Arthritis
Abstract Number: 1397

Temporal Trends in Early Rheumatoid Arthritis (ERA) Patients with Moderate to Severe Disease Activity: A Multicenter Cohort Study of Treatment Strategies and Outcomes in Chinese Patients in the Modern Era
Abstract Number: 1398

Difficult to Treat Rheumatoid Arthritis Incidence and Risk Factors in the Early Arthritis UCLouvain Brussels Cohort
Abstract Number: 1399

A First-in-Human Clinical Trial Evaluating the Safety and Pharmacokinetics of SOL-116, a Novel Humanized Monoclonal Antibody Targeting Bile Salt-Stimulated Lipase for the Treatment of RA
Abstract Number: 1400

Disease Modifying Anti-rheumatic Drug Use and Association with Survival in Patients with Rheumatoid Arthritis and Newly Diagnosed Lung Cancer
Abstract Number: 1401

Risk of Malignancy with TNF-α Inhibitors in Patients with Rheumatoid Arthritis
Abstract Number: 1402

Addressing Unmet Needs in Cannabis and Hemp by Improving Knowledge and Data Collection
Abstract Number: 1403

Development, Validation and Clinical Use of Health-Related Behaviour Health Fitness Questionnaire (HR-BHF) in Indian (Asian) Subjects Attending a Community Rheumatology Center
Abstract Number: 1404

Modeling Diversity in Systemic Lupus Erythematosus (SLE) Clinical Trials Using Real-world Data (RWD) Sources

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].